|8541572||Compounds for the treatment of inflammatory disorders|
This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or cond...
|8071762||Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor|
The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X1-X5, R5-R8b, Z1-Z2
|7714126||Diacylglycerol acyltransferase inhibitors|
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositi...
The present invention provides substituted puleganic amides and compositions thereof, which are both useful as a topical treatment for skin, such as a repellant for insects and arthropods. ...
|7393852||Piperazine derivatives and methods of use|
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for...
|7332511||Vanilloid receptor ligands and their use in treatments|
Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular an...
|7285565||Benzamides and related inhibitors of factor Xa|
Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. ...
|7285686||Process for the preparation of 1,3-substituted indenes|
An improved process for the preparation of 1,3 substituted indenes which are useful intermediates in the synthesis of aryl fused azapolycyclic compounds as agents for the treatment of neurological and psychological disorders. ...
|7273863||Benzophenones as inhibitors of reverse transcriptase|
The present invention includes benzophenone compounds (I) which are useful in the treatment of HIV infections. ...
|7256152||Composition of catalyst and solvent and catalysis processes using this composition|
A composition defined: either as comprising at least one Broensted acid, designated HB, dissolved in a liquid medium with an ionic nature of general formula Q+A−, in which Q+ represents an organic cation and A− represents an an...
|7256275||Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation|
This invention pertains to the field of combination oligomers, including the block synthesis of combination oligomers in the absence of a template, as well as related methods, kits, libraries and other compositions. ...
|7229803||Reaction of (di)amines in the presence of a lysine oxidase and of a reducing agent|
The invention relates to methods for reacting (di)amines as substrates in the presence of a lysine oxidase arid a reducing agent, resulting in alcohols, diols or cyclic secondary amines. In a particular embodiment, the invention is directed to methods of preparing c...
|7214714||20-hydroxyeicosatetraenoic acid production inhibitors|
A hydroxyformamidine compound represented by the following formula or a pharmaceutically acceptable salt thereof [wherein R1 represents a substituted morpholino group, a substituted piperidino group, a...
The invention relates to 5-HT receptor agonists or antagonists. Novel arylpiperazinyl sulfonamide compounds represented by Formulae I: and II, and synthesis and uses of those compounds for treating diseases including those mediated directly or indirectly by 5-HT rec...
|7141560||Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics|
The present invention relates to alanine 2,6-dialkoxyphenyl ester derivatives having the general formula I The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of th...
|7129228||Heterocyclic analgesic compounds and methods of use thereof|
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-couple...
|7112582||Bicyclic 6-alkylidene-penems as β-lactamase inhibitors|
The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof. wherein one of A and B den...
|7112679||Convergent synthesis of α-aryl-β-ketonitriles|
The present invention relates to processes for the production of α-aryl-β-ketonitriles, which serve as synthetic intermediates in the preparation of a series of biologically important molecules such as corticotropin releasing factor (CRF) receptor antagonists....
|7105507||Cyclohexane derivatives and their use as therapeutic agents|
The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R
|7060856||Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide|
This invention provides a novel polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, as well a pharmaceutical compositions and therapeutic methods utilizing the polymorphic form. ...
|7053085||EP receptor agonist, compositions and methods thereof|
This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a ...
|7053071||Induction of apoptosis in cancer cells|
The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of...
|7053212||Acyclic amide and sulfonamide ligands for the estrogen receptor|
The present invention provides estrogen receptor (ER) ligands of structural formula (I) the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the...
This invention relates to triazine compounds of formula (I): R1 is , aryl, or heteroaryl; each of R2, R4, and R5, independently,...
|7026510||Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them|
(R)-Enantiomers of quaternary ammonium salts of general formula (I) are described: where R, R1, R2, R3, X and Z are as defined in the description. The process for their preparati...
|7015217||Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)|
The present application describes novel cyclic sulfone derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α c...
|7001905||Substituted diarylamines as MEK inhibitors|
Diarylamines, such as 5-amide substituted diarylamines of formula (I) or formula (II) wherein A is hydroxy, C1-6 alkoxy, or NR6OR7; X is OR12, NR13R12, or NR14; inhibitors of MEK and are us...
|6995183||Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods|
Compounds are provided having the formula (I) wherein: n is 0, 1 or 2; m is 0, 1 or 2; the sum of n+m less then or equal to 2;
|6992081||Compounds to treat Alzheimer's disease|
The present invention is directed toward substituted hydroxyethylene compounds of formulas (XII) (XIII), and (XIV) useful in treating Alzheimer's disease and other similar diseases. ...
|6984639||Heterocyclic ketone and thioester compounds and uses|
This invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone and thioester compounds, compositions containing the same, and the use of such compounds for treating neurological disorders, including physically damaged nerves and neu...
|6972287||Method of inhibiting amyloid protein aggregation and imaging amyloid deposits|
The present invention provides a method of treating Alzheimer's disease using a compound of Formula (I). Also provided is a method of inhibiting the aggregation of amyloid proteins using a compound of the Formula (I) and a method of imaging amyloid deposits, as well...
This invention features pyrimidine compounds of formula (I): each of R2 and R4 is H; R3 is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alky...
|6943196||NF-κB inhibitor comprising phenylmethyl benzoquinone as the active ingredient|
An NF-κB inhibitor having as an active ingredient a benzoquinone derivative represented by the general formula (1) wherein R1, R2, and R3 are each independently H, alkyl having 1 to 5 carbons, or alkoxy having 1 to 5 carbons; R...
|6940092||Electrically conducting organic compound and electronic device|
An electrically conducting organic compound comprising a condensed polycyclic aromatic compound containing from 8 to 14 condensed rings and being solubilized in a solvent by the introduction of a functional group into any condensed ring of the compound. The electric...
|6916800||Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent|
The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor and an antineoplastic agent. ...
|6903092||Naphthamide neurokinin antagonists for use as medicaments|
Compounds having the general formula wherein R1, R2, R3, R4, R5, X1 and X2 are as defined in the specification, methods of using such compoun...
|6900350||Method for the production of ω-aminoalkylsulphonic acids|
The invention relates to a method for the production of ω-aminoalkylsulphonic acids of general formula (I), where R1 and R2=optionally substituted alkyl groups with 1 20 C atoms and n=a whole number from 2 6, whereby an amine of formula (II), where R1 and R2 have t...
|6900313||Chiral ionic liquids|
The invention relates to chiral ionic liquids of the general formula [A]n+[Y]n−, whereby n=1 or 2, the anion [Y]n− is the anion of an organic or inorganic proton acid and the cation [A]+ ...
|6897210||Quinazoline derivatives and pharmaceutical compositions containing them|
The invention relates to quinazoline derivatives of formula (I) wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR
|6858598||Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia|
A method of using an MMP inhibitor and optionally radiation therapy, and one or more antineoplastic agents of the topoisomerase class selected from the group consisting of irinotecan and topotecan, as a combination therapy for the treatment of neoplasia is disclosed...